Vesalius Therapeutics Announces Leadership TransitionShare Share on LinkedIn Share on Twitter Cambridge, Mass, March 7, 2024 –Vesalius Therapeutics, a company pioneering a radical approach to common disease drug development, today announced that John Mendlein, Ph.D., will become the company’s ...
At Vesalius Therapeutics, we believe it is time to re-think and redefine how we treat common illnesses. Founded by Flagship Pioneering , we are building a…
Vesalius Therapeutics是一家初创公司,通过将每种疾病视为具有不同生物学特征的许多不同疾病,正在挑战传统的常见疾病药物研究方法。它的技术使用患者数据和样本创建代表疾病的分子和数字人类化身。通过人工智能,维萨利厄斯旨在了解疾病差异,并将治疗方法与反应灵敏的患者相匹配。该公司已与葛兰素史克达成8000万美元的协议,验...
全球顶级风投公司Flagship Pioneering,是孵化生命科学创新企业的拓荒者,其中他们孵化的一家初创公司VesaliusTherapeutics。这是一家专注于重新定义常见疾病的理解和治疗的公司,他们致力于将人工智能和机器学习应用于常见疾病,Flagship Pioneering对其兑现了7500万美元的融资承诺,这家总部位于马萨诸塞州剑桥的初创公司于周三推出。
Six months after its launch, Vesalius Therapeutics is laying off 43% of its staff. With a current staff of 67, the company is slashing 29 jobs.
We invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data. The investment strategy is focused on three areas: therapeutics, medical ...